SCHEMBL13675547

SCHEMBL13675547

Cc1cccc(C)c1CC1CCNC1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.38
HTR1D P28221 1/20 0.38
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
PTGER3 P43115 2/20 0.35
DDB1 Q16531 2/20 0.34
CRBN Q96SW2 2/20 0.34
ALDH1A1 P00352 3/20 0.34
HSD17B10 Q99714 2/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALDH2 P05091 1/20 0.34
PDCD1 Q15116 1/20 0.34
CD274 Q9NZQ7 1/20 0.34
HTR2C P28335 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14365029 0.80 KMT2A (0.38) TAAR1DDB1CRBNALDH1A1HTT
SCHEMBL13675548 0.74 LMNA (0.41) TAAR1ALDH1A1HSD17B10PDCD1CD274
SCHEMBL13675555 0.74 PDCD1 (0.40) PDCD1CD274
SCHEMBL837901 0.74 DDB1 (0.60) DDB1CRBNALDH1A1KMT2A
SCHEMBL8070063 0.73 DDB1 (0.42) DDB1CRBNALDH1A1HTTKMT2A
SCHEMBL3051430 0.71 ALDH1A1 (0.44) DDB1CRBNALDH1A1HTTGAA
SCHEMBL4519254 0.71 GLA (0.38) TAAR1ALDH1A1HTTMEN1KMT2A
SCHEMBL4467894 0.70 PTGER3 (0.41) PTGER3CRBNALDH1A1HSD17B10HTR2C
SCHEMBL31047569 0.69 CRBN (0.31) PTGER3DDB1CRBN
SCHEMBL4961020 0.68 ALDH1A1 (0.50) DDB1CRBNALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 TAAR1 2616/4885HTR1D 2262/4885PARP1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.